Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment

Assessing the Effectiveness of Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment: a Pilot Study

This pilot randomized controlled trial is to investigate the feasibility and efficacy of cognitive rehabilitation for patients with post-COVID-19 cognitive impairment. Additionally, the study will obtain preliminary data, using rsfMRI, regarding the potential underlying connectivity networks, mediating the effect of CR on cognitive improvements.

Inclusion Criteria:

• Adults ≥18 years of age
• Have a confirmed SARS-CoV-2 infection (positive PCR or are serum antibody positive [against spike protein if unvaccinated or N-capsid peptide if vaccinated])
• Speak English
• Have objective mild to moderate cognitive impairment, which will be defined as impairment in executive function (a z-score >1.5 standard deviations below the normative mean) and in at least one other cognitive domain
• Endorse comfort and familiarity with technology.

Exclusion Criteria:

• No method of contact
• Major neurocognitive disorder, as defined by a score <17 on the Montreal Cognitive Assessment (MoCA)
• History of pre-COVID-19 neurologic disease (e.g., stroke)
• History of severe head injury (as defined by loss of consciousness >30 minutes)
• Ongoing substance use disorder (Mini International Neuropsychiatric Interview Version 7.0.2 [MINI] or Alcohol Use Disorders Test-Consumption [AUDIT-C] >8)
• Unstable medical, neurologic, or psychiatric conditions precluding participation in research activities, and
• Contraindication for MRI (e.g., metallic/electronic implants).
• Not involved in cognitive rehabilitation/training or daily meditative practices during study enrollment